Biosimilar Insulins: How Similar is Similar?
نویسندگان
چکیده
منابع مشابه
Biosimilar insulins: how similar is similar?
Biosimilar insulins (BIs) are viewed as commercially attractive products by a number of companies. In order to obtain approval in the European Union or the United States, where there is not a single BI currently on the market, a manufacturer needs to demonstrate that a given BI has a safety and efficacy profile that is similar to that of the "original" insulin formulation that is already on the...
متن کاملHow similar is similar?
ion on which similarity between musical entities can be measured. Then, each of these concepts is examined in more detail with respect to a number of research studies presented in the recent special issue of Musicæ Scientiæ on musical similarity (Discussion Forum 4A, 2007). Views claiming that a geometric piano-roll-like representation is the most appropriate choice for polyphonic pattern match...
متن کاملThe first biosimilar epoetin: but how similar is it?
R educing health costs is a hot political issue in many countries, so the introduction and use of generic drugs is stimulated. The generics may be introduced when the patent of an innovative drug expires. With classic drugs, normally produced by chemical synthesis, only limited data for marketing approval application are needed compared with the original drug (1). The generic manufacturer needs...
متن کاملEntity Matching: How Similar Is Similar
Entity matching that finds records referring to the same entity is an important operation in data cleaning and integration. Existing studies usually use a given similarity function to quantify the similarity of records, and focus on devising index structures and algorithms for efficient entity matching. However it is a big challenge to define “how similar is similar” for real applications, sinc...
متن کاملThe Future of Biosimilar Insulins
IN BRIEF Biosimilar insulins are available in many countries and will be made available in the United States in the near future. Some concerns associated with biosimilar insulins include potential differences in the efficacy and safety between a biosimilar product and its reference insulin, the ramifications of having the same name or different names for a biosimilar and its reference insulin, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Diabetes Science and Technology
سال: 2011
ISSN: 1932-2968,1932-2968
DOI: 10.1177/193229681100500329